TransCardiac Therapeutics, Inc.'s Chief Scientific Officer Presents Mitral Valve Repair Device at TCT Conference
Atlanta, GA, October 30, 2013 --(PR.com)-- TransCardiac Therapeutics Inc.'s ("TCT" or the "Company") Chief Scientific Officer, Dr. Omar Lattouf, was invited by the organizers of the Transcatheter Cardiovascular Therapeutics conference to present the Company's minimally invasive mitral valve repair device, the TransCardiac MitraFlex.
Dr. Lattouf outlined the history of his disruptive technologies to a room filled with cardiologists, cardiac surgeons, medical device developers, and investors. In 2001 Lattouf began to develop a minimally invasive method to insert epicardial pacemaker leads in heart failure patients who were suffering from inter-ventricular conduction block and who had failed the trans-venous route for Cardiac Resynchronization Therapy. Such patients had severely weakened heart function compounded with varying severity of Mitral Regurgitation and could not withstand open chest operations, Dr. Lattouf commented.
“As operating cardiac surgeon, I was troubled to perform incomplete repair on such sick patients; fixing the heart block but leaving the leaky and dysfunctional valve untreated," he observed. "Once faced with that challenge I began in 2001 to develop and subsequently invented a trans-apical access port, which can be temporarily or permanently inserted into the apex of the beating heart in order to safely introduce catheters and devices to repair the incompetent mitral valve and potentially address other structural heart problems."
Dr. Lattouf presented to the audience a contract research study by TCT which was conducted at the Emory / Georgia Tech Biomedical Engineering Labs comparing the "Alfieri edge to edge technique" to TransCardiac’s "stitch and chord" technique.
In that study TCT's patented trans-apically placed "stitch and chord," commonly referred to by the proprietary name the TransCardiac MitraFlex, reduced the mitral regurgitant volume from an average of 67% to 39%; which was 18% better and statistically more significant than the Alfieri stitch technique could accomplish.
Dr. Lattouf concluded his presentation noting that: (1) TransCardiac's MitraFlex “stitch and chord” may be superior to bow-tie stitch alone; (2) Single or multiple mitral chordal trans-apical replacements are feasible; (3) The TransCardiac MitraFlex may be the surgical minimally invasive alternative to more complex trans septal routes for applying an Alfieri type repair.
About TCT
TransCardiac Therapeutics, Inc. ("TCT" or the "Company") is a privately held medical device company focused on developing minimally invasive technology for cardiac repair. The company's proprietary devices include the TransCardiac MitraFlex for the repair of the mitral valve. TCT was founded in 2001 by Dr. Omar Lattouf MD PHD FACC FACS, Professor of Surgery at Emory University and Chief Scientific Officer at TCT. The Company's intellectual property had initially been developed by him at Emory University and subsequently released by Emory University and licensed to his company TransCardiac Therapeutics, Inc.
Contact: info[at]transcardiac.com
Dr. Lattouf outlined the history of his disruptive technologies to a room filled with cardiologists, cardiac surgeons, medical device developers, and investors. In 2001 Lattouf began to develop a minimally invasive method to insert epicardial pacemaker leads in heart failure patients who were suffering from inter-ventricular conduction block and who had failed the trans-venous route for Cardiac Resynchronization Therapy. Such patients had severely weakened heart function compounded with varying severity of Mitral Regurgitation and could not withstand open chest operations, Dr. Lattouf commented.
“As operating cardiac surgeon, I was troubled to perform incomplete repair on such sick patients; fixing the heart block but leaving the leaky and dysfunctional valve untreated," he observed. "Once faced with that challenge I began in 2001 to develop and subsequently invented a trans-apical access port, which can be temporarily or permanently inserted into the apex of the beating heart in order to safely introduce catheters and devices to repair the incompetent mitral valve and potentially address other structural heart problems."
Dr. Lattouf presented to the audience a contract research study by TCT which was conducted at the Emory / Georgia Tech Biomedical Engineering Labs comparing the "Alfieri edge to edge technique" to TransCardiac’s "stitch and chord" technique.
In that study TCT's patented trans-apically placed "stitch and chord," commonly referred to by the proprietary name the TransCardiac MitraFlex, reduced the mitral regurgitant volume from an average of 67% to 39%; which was 18% better and statistically more significant than the Alfieri stitch technique could accomplish.
Dr. Lattouf concluded his presentation noting that: (1) TransCardiac's MitraFlex “stitch and chord” may be superior to bow-tie stitch alone; (2) Single or multiple mitral chordal trans-apical replacements are feasible; (3) The TransCardiac MitraFlex may be the surgical minimally invasive alternative to more complex trans septal routes for applying an Alfieri type repair.
About TCT
TransCardiac Therapeutics, Inc. ("TCT" or the "Company") is a privately held medical device company focused on developing minimally invasive technology for cardiac repair. The company's proprietary devices include the TransCardiac MitraFlex for the repair of the mitral valve. TCT was founded in 2001 by Dr. Omar Lattouf MD PHD FACC FACS, Professor of Surgery at Emory University and Chief Scientific Officer at TCT. The Company's intellectual property had initially been developed by him at Emory University and subsequently released by Emory University and licensed to his company TransCardiac Therapeutics, Inc.
Contact: info[at]transcardiac.com
Contact
TransCardiac Therapeutics, Inc.
Omar Lattouf
678 957 1801
Omar Lattouf
678 957 1801
Contact
Categories